Literature DB >> 21748695

MR evaluation of retroperitoneal fibrosis.

L Kamper1, A S Brandt, C Scharwächter, S Kukuk, S Roth, P Haage, W Piroth.   

Abstract

PURPOSE: Retroperitoneal fibrosis (RPF) is a rare fibrosing process. The relation of contrast enhancement within the fibrosis and the psoas muscle was suggested for the evaluation of disease activity and response to treatment, but no standardized method for the quantification of the disease activity is currently available. We introduce an MR parameter for the evaluation of RPF.
MATERIALS AND METHODS: 29 patients with untreated idiopathic RPF were examined before medical therapy and after three months of treatment. MR analyses included quotients of T 1 and T 2-signal intensities between the RPF and the psoas muscle. Furthermore, we examined the dynamic contrast enhancement of the fibrous tissue. The respective data were compared with the extent of the RPF after 3 months.
RESULTS: In the follow-up examinations we observed a significant regression in 37.9 % (n = 11) of cases, a mild regression in 48.3 % (n = 14) and a stable extent in 13.8 % (n = 4). Patients with a significantly reduced extent showed the highest mean values for the applied MR quotients in the initial examination. The lowest mean values for the respective parameters were found for the group with a stable extent. Only dynamic enhancement quotients showed statistically significant differences (p = 0.011) between the groups of response.
CONCLUSION: We observed a significant reduction in the fibrous tissue after pharmacological treatment in patients with an elevated dynamic enhancement quotient in the initial examination. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748695     DOI: 10.1055/s-0031-1273450

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  12 in total

1.  The potential role of modern US in the follow-up of patients with retroperitoneal fibrosis.

Authors:  Lars Kamper; Alexander Sascha Brandt; Hendrik Ekamp; Matthias Hofer; Stephan Roth; Patrick Haage; Werner Piroth
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 2.  [Diagnosis and treatment of retroperitoneal fibrosis].

Authors:  A S Brandt; S Kukuk; N M Dreger; E Müller; S Roth
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

3.  The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis.

Authors:  Gabriella Moroni; Massimo Castellani; Aurora Balzani; Roberto Dore; Nicola Bonelli; Selena Longhi; Isabella Martinelli; Piergiorgio Messa; Paolo Gerundini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-17       Impact factor: 9.236

4.  Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis.

Authors:  Lars Kamper; Alexander Sascha Brandt; Hendrik Ekamp; Nadine Abanador-Kamper; Werner Piroth; Stephan Roth; Patrick Haage
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

5.  Diffusion-weighted MRI and PET-CT in the follow up of chronic periaortitis.

Authors:  L Kamper; N M Dreger; A S Brandt; T Pöppel; N Abanador-Kamper; S Roth; P Haage
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-15       Impact factor: 2.357

6.  (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease.

Authors:  Verena Ruhlmann; Thorsten Dirk Poeppel; Alexander Sascha Brandt; Johannes Grüneisen; Marcus Ruhlmann; Jens Matthias Theysohn; Michael Forsting; Andreas Bockisch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-11       Impact factor: 9.236

7.  Diffusion-weighted MRI in the follow-up of chronic periaortitis.

Authors:  L Kamper; P Haage; A S Brandt; W Piroth; N Abanador-Kamper; S Roth; H Ekamp
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

8.  [Therapy of retroperitoneal fibrosis: functional therapeutic outcome].

Authors:  A S Brandt; S Kukuk; N M Dreger; E Müller; S Roth
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

9.  [Retroperitoneal fibrosis: development of a biomarker profile for diagnosis and therapy monitoring].

Authors:  S Kukuk; A Kretschmer; H Bruck; S Roth; A S Brandt
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

10.  [Infrarenal aortic ectasia in retroperitoneal fibrosis (RPF)].

Authors:  Hendrik Ekamp; Patrick Haage; Alexander Sascha Brandt; Stephan Roth; Werner Piroth; Lars Kamper
Journal:  Wien Med Wochenschr       Date:  2012-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.